Prevalence and Characteristics of Patients With Systemic Sclerosis Fulfilling the 2019 EULAR/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

Abstract

ObjectiveThere is limited literature describing the overlap of systemic sclerosis (SSc) and systemic lupus erythematosus (SLE), and the studies have employed a range of case definitions. Our study used the new EULAR/American College of Rheumatology (ACR) SLE classification criteria to define SSc‐SLE cases among our center's SSc cohort.MethodsThis is a single‐center, retrospective study of a previously described cohort of patients with SSc. Patient data were re‐abstracted to evaluate for fulfillment of the 2019 EULAR/ACR classification criteria for SLE. Demographic, laboratory, clinical features, and mortality were compared among patients with SSc‐SLE and patients with SSc alone.ResultsAmong the 402 patients with SSc that were analyzed, 40 (10%) fulfilled the 2019 EULAR/ACR SLE classification criteria. Neuropsychiatric and renal involvement were rare. An initial SLE diagnosis was purported in 43% of the patients with SSc‐SLE and 7% of patients with SSc alone (P < 0.001). Patients with SSc‐SLE were more likely to be female, African American, and with limited cutaneous SSc. Anti–U1‐RNP antibody positivity prevalence was 30% among patients with SSc‐SLE and 6.6% among patients with SSc alone (P < 0.001). Death during follow‐up occurred in 12 patients (30%) with SSc‐SLE and in 81 patients (22%) with SSc alone, but there was no difference in survival among the groups per log rank test (P = 0.404).ConclusionTen percent of patients with SSc fulfill the 2019 EULAR/ACR classification criteria for SLE. These patients comprise a distinct demographic, serologic, and clinical phenotype but have similar severe SSc‐specific end‐organ damage and mortality as patients with SSc alone. Patients with SLE with Raynaud phenomenon should be evaluated for SSc‐specific autoantibodies and scleroderma organ involvement.